

1 **Title:**

2 Healthcare Cost of Stargardt Disease

3

4 **Authors:**

5 Kanza Aziz<sup>1</sup>, Bonnielin K. Swenor<sup>1,2</sup>, Joseph K. Canner<sup>3</sup>, Mandeep S. Singh<sup>1\*</sup>

6

7 **Affiliations:**

8 <sup>1</sup>Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA

9 <sup>2</sup>Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore,  
10 MD, USA

11 <sup>3</sup>Johns Hopkins Surgery Center for Outcomes Research, Johns Hopkins University School of  
12 Medicine, Baltimore, MD, USA

13

14 **\*Corresponding author:**

15 Address: Wilmer Eye Institute, Johns Hopkins University School of Medicine, 600 N. Wolfe  
16 Street, Baltimore, MD 21287

17 Email: [mandeep@jhmi.edu](mailto:mandeep@jhmi.edu)

18

19

20 **Meeting Presentation:**

21 Partial analyses were presented as a poster at the Association for Research in Vision and  
22 Ophthalmology Annual Meeting 2018 (published abstract: Aziz et al., Healthcare Costs of  
23 Stargardt Disease. *Investigative Ophthalmology & Visual Science* July 2018, Vol.59, 5221)

24

25 **Financial Support:**

26 Foundation Fighting Blindness (MSS), Joseph Albert Hekimian Fund (MSS), National Institute  
27 on Aging K01AG052640 (BKS), Research to Prevent Blindness (unrestricted grant to the  
28 Wilmer Eye Institute)

29

30 **Conflict of Interest:**

31 No conflicting relationship exists for any author

32

33 **Word Count:** 2315

34 **Abstract**

35 **Importance:** Stargardt disease (SD) is the most common juvenile macular degeneration and a  
36 leading cause of uncorrectable childhood blindness. The progressive and incurable nature of this  
37 chronic condition entails a long-term financial burden on affected individuals. The economic costs  
38 of SD have not been characterized in detail.

39 **Objective:** To estimate the direct healthcare cost of SD.

40 **Design:** Cross-sectional analysis of healthcare claims.

41 **Participants:** Patients with an ICD-9 diagnosis code of SD, non-exudative age-related macular  
42 degeneration (AMD), or bilateral sensorineural hearing loss (SHL).

43 **Methods:** Outpatient administrative claims data from the IBM® MarketScan® Commercial  
44 Claims and Encounters Database from 2010 to 2014 were analyzed.

45 **Main Outcome Measure:** Annual per-patient direct healthcare cost.

46 **Results:** A total of 472,428 patients were analyzed (5,015 SD, 369,750 SHL and 97,663 AMD  
47 patients respectively). The payment per year of insurance coverage for SD (median: \$105.58, IQR:  
48 \$50.53-\$218.71) was higher than that of SHL (median: \$51.01, IQR: \$25.66-\$121.66,  $p < 0.001$ )  
49 and AMD (median: \$76.20, IQR: \$38.00-\$164.86,  $p < 0.001$ ). When adjusted for covariates, the  
50 annual payment for SD was \$47.83 higher than SHL ( $p < 0.001$ ) and \$17.34 higher than AMD  
51 ( $p < 0.001$ ).

52 **Conclusions and Relevance:** There is a significant direct healthcare cost associated with SD. The  
53 annual per-patient cost of SD was higher than SHL, another condition that causes sensory  
54 impairment in people of all ages, and nonexudative AMD which causes a similar pattern of visual

55 loss that typically begins later in life. The total lifetime per-patient cost of SD may exceed that of  
56 nonexudative AMD.

## 57 **Introduction**

58 Stargardt disease (SD) is the most common form of inherited macular degeneration, and is caused  
59 by mutations in the *ABCA4* gene. Its reported incidence is 1 in 8,000 - 10,000<sup>1</sup>. People with SD  
60 typically begin to experience progressive visual loss as children or young adults<sup>2</sup>. Although there  
61 is no cure at present, several possible treatments including pharmacologic, stem cell, and gene  
62 therapy modalities are being evaluated in clinical trials<sup>3,4</sup>. Without treatment, vision loss in SD is  
63 typically progressive. Approximately one decade after symptom onset, visual acuity typically  
64 reaches the 20/100 to 20/200 level<sup>5,6</sup>. Management strategies for symptomatic patients currently  
65 include disease monitoring, counseling, and low vision rehabilitation. When coupled with the  
66 current lack of treatment options, the progressive nature of SD entails long-term healthcare-related  
67 financial implications for patients. Furthermore, available data suggest that early-onset SD tends  
68 to run a more severe course, and causes severe permanent vision loss earlier in life, than later-  
69 onset SD<sup>3,7</sup>. Those affected by earlier SD onset may require more medical care and therefore incur  
70 greater costs.

71 There is a paucity of information on the healthcare costs of SD. Presumably this is because SD is  
72 regarded as a rare disease, unlike age related macular degeneration (AMD)<sup>8,9</sup>. The global AMD  
73 treatment market is expected to reach \$11.6 billion by 2026<sup>10</sup>. SD is currently the target of  
74 therapeutic development; estimates of the healthcare costs associated with SD would be useful in  
75 determining the total impact of these therapies. Healthcare costs have significant implications for  
76 both the individual and society because these costs constitute an important driving factor behind  
77 healthcare policy and economics, especially for chronic diseases such as SD.

78 To better understand healthcare costs associated with SD in the context of other disease conditions,  
79 we also analyzed the costs associated with non-exudative AMD and bilateral sensorineural hearing

80 loss (SHL) as controls. The rationale for selecting non-exudative AMD was that the typical pattern  
81 of vision loss during the course of disease is analogous to SD to some degree. The macula is the  
82 site of retinal cell degeneration in both these conditions. Therefore, central, rather than peripheral,  
83 vision loss is progressively compromised over time, and is the chief source of vision-related  
84 disability and healthcare-seeking behavior in both conditions. We selected SHL as another control  
85 because it is the impairment of a sensory system, other than vision, that affects younger individuals  
86 and entails long-term healthcare cost implications. Therefore, the aim of this study was to estimate  
87 the direct healthcare costs of SD as compared to non-exudative AMD and SHL.

88

## 89 **Methods**

### 90 *Data Source*

91 Outpatient insurance claims data from 2010 to 2014 were analyzed using the IBM® MarketScan®  
92 Commercial Claims and Encounters Database. MarketScan® is a large database containing  
93 adjudicated and paid insurance claims data of individuals and their dependents whose health  
94 insurance is provided by their employers. These include active employees, early retirees and  
95 Consolidated Omnibus Budget Reconciliation Act (COBRA) continuers. Most of the data are  
96 collected from large employers and health plans. The types of benefit plans include  
97 comprehensive, exclusive provider organization (EPO), health maintenance organization (HMO),  
98 preferred provider organization (PPO), consumer directed health plan (CDHP), high deductible  
99 health plan (HDHP) and point-of-service (POS) plans with and without capitation. A unique  
100 identifier assigned to each patient is coded on claims. The dataset complies with Health Insurance  
101 Portability and Accountability Act regulations for a limited data-set and has undergone a third

102 party review for a fully de-identified dataset<sup>11</sup>. The study was approved by the Johns Hopkins  
103 Medicine Institutional Review Board.

#### 104 *Study Population*

105 Claims with a primary diagnosis of SD, SHL and AMD were selected using ICD-9 diagnosis codes  
106 362.75, 389.18 and 362.51, respectively. Claims with missing procedure codes were excluded. The  
107 unique patient identifier coded on claims was used to associate claims to each patient. In cases  
108 where a patient had more than one diagnosis, the primary diagnosis was used for categorization.  
109 Patients aged <50 years with a diagnosis of AMD were assumed to have been misdiagnosed or  
110 mis-coded and so were excluded from analysis.

111 SHL patients with cochlear implants were excluded due to lack of a comparable device to improve  
112 function in SD. Patients with exudative AMD, cystoid macular degeneration, macular cyst, hole  
113 or pseudohole, macular pucker or toxic maculopathy were excluded.

#### 114 *Statistical Analyses*

115 The gross median payments to providers for health services per year of insurance coverage were  
116 calculated for SD, SHL and AMD. We accounted for periods of non-coverage by considering only  
117 the total number of insured days for each patient.

118 Categorical variables were reported as frequencies and percentages while continuous variables  
119 were reported as medians with interquartile ranges. The Wilcoxon rank-sum test was used to test  
120 for statistical differences in the number of insurance claims per covered year and payments per  
121 covered year between groups. A multivariable quantile regression was used to adjust for covariates  
122 and analyze payments per covered year for each condition. Furthermore, a multivariable quantile  
123 regression model was used to compare payments per covered year between SD and SHL.

124 Additional multivariable regression models were used to compare payments per covered year for  
125 SD with patients restricted to those aged  $\geq 50$  years and AMD for a more effective comparison.  
126 Covariates selected for the regression models included age (continuous variable), gender (male or  
127 female), year of first service in the database (2010-2014) and type of benefit plans (PPO,  
128 comprehensive, HMO, PPO with and without capitation, POS, CDHP and HDHP). The covariates  
129 were categorized as in the database.

130 A two-tailed P value of  $<0.05$  was considered to be statistically significant. All statistical analyses  
131 were performed using Stata/MP version 14.2 (StataCorp LLC, College Station, TX).

132

## 133 **Results**

### 134 *Population Characteristics*

135 A total of 472,428 patients were analyzed (Table 1). Of these were 5,015 (1.1%) patients with SD,  
136 369,750 (78.3%) with SHL, and 97,663 (20.7%) with AMD. Patients with SD (median age: 41  
137 years, IQR [interquartile range]: 23-53 years) were younger than those with SHL (median age: 54  
138 years, IQR: 44-60 years,  $p < 0.001$ ), and AMD (median age: 60 years, IQR: 56-62 years,  $p < 0.001$ ).  
139 The majority of SD and AMD patients were female (55.0% and 58.9%, respectively), whereas the  
140 majority of SHL patients were male (53.0%). The mean total number of gaps in insurance coverage  
141 per patient was  $0.13 \pm 0.41$ .

### 142 *Healthcare utilization*

143 The number of insurance claims per year for SD patients (median: 0.51, IQR: 0.33-1.00) was  
144 greater than in SHL (median: 0.40, IQR: 0.25-0.67,  $p < 0.001$ ) and in AMD (median: 0.50, IQR:

145 0.32-1.00,  $p < 0.001$ ). The most common healthcare service utilized for SD patients was fundus  
146 photography ( $n=2,614$ , 11.98%). Medical examination and evaluation ( $n=57,950$ , 15.32%) was  
147 the most common healthcare service in AMD. Comprehensive audiometry threshold evaluation  
148 and speech recognition ( $n=308,619$ , 27.42%) was the most common healthcare service in SHL.  
149 Table 2 details the top five services utilized in each group.

### 150 *Healthcare costs*

151 Payments per year for SD (median [IQR], \$105.58 [\$50.53-\$218.71]) were greater than for SHL  
152 (\$51.01 [\$25.66-\$121.66],  $p < 0.001$ ) and AMD (\$76.20 [\$38.00-\$164.86],  $p < 0.001$ ). Table 3  
153 presents the regression analysis for payments for each condition, adjusting for age, sex, type of  
154 benefit plan and year of first service.

155 For SD patients, female gender was associated with higher annual payments as compared to males  
156 ( $p=0.03$ ). However, older age (per year) was associated with lower payments of \$0.75 per year.  
157 Annual payments varied by type of plan (HMO \$15.73 lower than PPO,  $p=0.012$ ).

158 For SHL, EPO plans were associated with higher payments per year (\$6.99) than PPO plans  
159 ( $p < 0.001$ ). Factors associated with lower payments included higher age, female gender, year of  
160 first service in the database (2011-2014), and type of plan.

161 For AMD, older age (per year) was associated with an additional \$1.60 payment ( $p < 0.001$ ).  
162 Payments for females were \$3.22 higher than those for males ( $p < 0.001$ ). Those with POS with  
163 capitation plans incurred \$10.02 more per year than those with PPO plans ( $p=0.014$ ).

164 When comparing payments per year for SD to those for SHL, adjusted payments per year were  
165 significantly higher for SD patients (Table 4). The adjusted median payments for SD was \$ 101.06  
166 (95% confidence interval [CI]: \$ 98.92-\$ 103.20) and \$53.23 (95%CI: \$52.98-\$53.48) for SHL.



167 The difference in payments per year was \$47.83 (95% CI: \$45.67 - \$49.98,  $p < 0.001$ ). EPO plans  
168 were associated with higher payments per covered year.

169 Because of the age difference in SD and AMD patients, we also compared the AMD data with that  
170 of SD patients aged  $\geq 50$  years ( $n = 1,669$ ) (Table 5). A similar trend in the result was observed. The  
171 adjusted median payment for SD patients aged  $\geq 50$  years was \$96.43 (95% CI: \$91.35-\$101.51)  
172 and was \$79.09 (95% CI: \$78.43-\$79.74) for AMD. Therefore, payments for SD patients were  
173 \$17.34 higher than for AMD (95% CI: \$12.22 - \$22.47,  $p < 0.001$ ). Factors associated with  
174 significantly greater payments included older age, female gender, and type of benefit plan (POS  
175 with capitation).

176

## 177 **Discussion**

178 The data show that there is a significant annual healthcare cost associated with SD. Payments  
179 associated with SD were higher than two control conditions, SHL and AMD. Payments also  
180 appeared to be influenced by patient gender, possibly due to differences in gender-related disease  
181 progression<sup>12</sup> or health-seeking behavior<sup>13</sup>. To our knowledge, this is the first published estimate  
182 of the direct healthcare costs associated with SD.

183 The annual unadjusted median cost for patients with SD in our study, using only the MarketScan  
184 commercial claims and encounters database, was \$105.58. A prior study estimated the healthcare  
185 costs of retinitis pigmentosa (RP), another inherited degenerative retinal disease, to be \$3206 per  
186 patient<sup>14</sup>. This is higher than the figure reported by our study. This difference could be related to  
187 the fact that the RP study included both the MarketScan<sup>®</sup> commercial claims and encounters and  
188 the Medicare supplemental datasets. Also, the RP study included claims with an ICD-9 diagnosis

189 of retinitis pigmentosa in both the primary or secondary diagnosis position. In this study, we  
190 limited the analyzed claims to those with a primary diagnosis of SD. While limiting the dataset,  
191 this enhances the specificity of results to SD-related healthcare encounters. Future studies on the  
192 costs of SD could integrate multiple datasets to see if the SD-related costs are comparable to those  
193 of RP.

194 Greater awareness of the economic burden of SHL and AMD exists possibly because of their  
195 higher prevalence than SD. In one study which used Medicare data, the annual per-patient cost for  
196 dry AMD was reported to be \$204.43<sup>8</sup>, a higher amount than we found. This difference could be  
197 due to the use of a different database, with an older population. A study from United Kingdom,  
198 including children aged 7 to 9 years with congenital bilateral hearing impairment, reported an  
199 annual per-patient healthcare cost of \$2808, again higher than in our data. The study only included  
200 children with over 60 dB hearing loss, relied mostly on self-reported cost information from parents,  
201 included costs related to inpatient care and the use of community and social care services, as well  
202 as the cost of cochlear implants, hearing aids, and other assistive devices such as loop systems and  
203 special alarm clocks<sup>15,16</sup>.

204 One of the potential factors driving the high total healthcare costs for SD is the relatively early  
205 onset of disease. SD is usually diagnosed in the second or third decades of life and the associated  
206 visual loss is progressive thereafter. The total direct costs of diseases that present at an early age  
207 could be higher than diseases that present later, due to accumulation of costs over time. While this  
208 study does not address the impact of the disease on productivity and quality of life, one can  
209 extrapolate that a disease with onset at earlier ages would lead to a greater lifetime impact on  
210 productivity and quality of life than diseases that occur in late life. Vision impairment has a  
211 significant impact on education, employment, productivity, and independence of daily living.

212 Vision impairment is also associated with falls, injuries, reduced mobility, depression, poor health  
213 outcomes, and reduced quality of life<sup>17</sup>. One study reported that the total economic burden,  
214 including direct and indirect costs, was \$27.5 billion per year (2012 dollars) among people aged  
215 40 years and younger with eye disorders<sup>18</sup>. Estimates of the total economic burden of SD, and its  
216 indirect costs, are not yet available.

217 This study has several limitations. First, the data were limited to patients younger than 65 years.  
218 Therefore, the overall costs might be under-reported for AMD. Second, the dataset used for the  
219 current study does not include Medicare and Medicaid data, and therefore these costs are not  
220 included. Third, individuals who are uninsured or unemployed were not captured in the  
221 MarketScan database, because it includes only employment-based claims. Fourth, since there is  
222 no treatment available for SD, a vast majority of the patients rely on low vision devices, especially  
223 in the later stages of the disease<sup>19</sup>. These low vision devices are not covered by many insurance  
224 companies in the United States and therefore the associated cost was not fully captured herein.  
225 Further, the nature of any administrative claims database is such that there is a possibility of  
226 diagnosis and procedure codes not being recorded in a standardized way. Lastly, disease stage or  
227 severity was not considered in this study.

228 Further research could explore other datasets, and include the costs attributable to low vision aids,  
229 guide dogs, loss of productivity, reduction in hours worked, and caregiver costs. It would also be  
230 useful to evaluate visual function and disease severity in relation to economic impact. The  
231 development of novel therapeutic modalities such as retinal stem cell and gene therapy<sup>3,20-27</sup> are  
232 likely to affect the long-term economic burden associated with SD.

233

234 **Conclusion**

235 In this limited dataset, the annual per-patient costs of SD were found to be higher than those  
236 incurred by patients with bilateral SHL and non-exudative AMD. The total lifetime per-patient  
237 cost of SD may exceed that of non-exudative AMD, due to the earlier age of onset of the former  
238 condition. There is a need to develop cost-effective treatments for SD, to reduce the long-term  
239 economic burden associated with this condition.

## 240 **References**

- 241 1. Walia S, Fishman GA. Natural history of phenotypic changes in Stargardt macular  
242 dystrophy. *Ophthalmic Genet.* 2009;30(2):63-68. doi:10.1080/13816810802695550
- 243 2. Haji Abdollahi S, Hirose T. Stargardt-Fundus flavimaculatus: recent advancements and  
244 treatment. *Semin Ophthalmol.* 2013;28(5-6):372-376. doi:10.3109/08820538.2013.825286
- 245 3. Lu LJ, Liu J, Adelman RA. Novel therapeutics for Stargardt disease. *Graefes Arch Clin Exp*  
246 *Ophthalmol.* 2017;255(6):1057-1062. doi:10.1007/s00417-017-3619-8
- 247 4. Auricchio A, Trapani I, Allikmets R. Gene Therapy of ABCA4-Associated Diseases. *Cold*  
248 *Spring Harb Perspect Med.* 2015;5(5):a017301. doi:10.1101/cshperspect.a017301
- 249 5. Tanna P, Strauss RW, Fujinami K, Michaelides M. Stargardt disease: clinical features,  
250 molecular genetics, animal models and therapeutic options. *British Journal of*  
251 *Ophthalmology.* August 2016;bjophthalmol-2016-308823. doi:10.1136/bjophthalmol-2016-  
252 308823
- 253 6. Armstrong JD, Meyer D, Xu S, Elfervig JL. Long-term follow-up of Stargardt's disease and  
254 fundus flavimaculatus. *Ophthalmology.* 1998;105(3):448-457; discussion 457-458.  
255 doi:10.1016/S0161-6420(98)93026-3
- 256 7. Westeneng-van Haften SC, Boon CJF, Cremers FPM, Hoefsloot LH, den Hollander AI,  
257 Hoyng CB. Clinical and genetic characteristics of late-onset Stargardt's disease.  
258 *Ophthalmology.* 2012;119(6):1199-1210. doi:10.1016/j.ophtha.2012.01.005
- 259 8. Halpern MT, Schmier JK, Covert D, Venkataraman K. Resource utilization and costs of  
260 age-related macular degeneration. *Health Care Financ Rev.* 2006;27(3):37-47.
- 261 9. Schmier JK, Jones ML, Halpern MT. The burden of age-related macular degeneration.  
262 *Pharmacoeconomics.* 2006;24(4):319-334.
- 263 10. Macular Degeneration Treatment Market Size, Share, Trends | Forecast 2026.  
264 <https://www.acumenresearchandconsulting.com/macular-degeneration-treatment-market>.  
265 Accessed May 10, 2019.
- 266 11. Hansen L. The Truven Health MarketScan Databases for life sciences researchers. :24.
- 267 12. Zahid S, Jayasundera T, Rhoades W, et al. Clinical phenotypes and prognostic full-field  
268 electroretinographic findings in Stargardt disease. *Am J Ophthalmol.* 2013;155(3):465-  
269 473.e3. doi:10.1016/j.ajo.2012.09.011
- 270 13. Bertakis KD, Azari R, Helms LJ, Callahan EJ, Robbins JA. Gender differences in the  
271 utilization of health care services. *J Fam Pract.* 2000;49(2):147-152.

- 272 14. Frick KD, Roebuck MC, Feldstein JI, McCarty CA, Grover LL. Health services utilization  
273 and cost of retinitis pigmentosa. *Arch Ophthalmol*. 2012;130(5):629-634.  
274 doi:10.1001/archophthalmol.2011.2820
- 275 15. Schroeder L, Petrou S, Kennedy C, et al. The economic costs of congenital bilateral  
276 permanent childhood hearing impairment. *Pediatrics*. 2006;117(4):1101-1112.  
277 doi:10.1542/peds.2005-1335
- 278 16. World Health Organization. *Global Costs of Unaddressed Hearing Loss and Cost-  
279 Effectiveness of Interventions.*; 2017.  
280 <http://apps.who.int/iris/bitstream/10665/254659/1/9789241512046-eng.pdf>. Accessed  
281 September 16, 2019.
- 282 17. Read “*Making Eye Health a Population Health Imperative: Vision for Tomorrow*” at  
283 *NAP.Edu*. doi:10.17226/23471
- 284 18. Wittenborn JS, Zhang X, Feagan CW, et al. The economic burden of vision loss and eye  
285 disorders among the United States population younger than 40 years. *Ophthalmology*.  
286 2013;120(9):1728-1735. doi:10.1016/j.ophtha.2013.01.068
- 287 19. Collee CM, Jalkh AE, Weiter JJ, Friedman GR. Visual Improvement with Low Vision Aids  
288 in Stargardt’s Disease. *Ophthalmology*. 1985;92(12):1657-1659. doi:10.1016/S0161-  
289 6420(85)34086-1
- 290 20. Schwartz SD, Hubschman J-P, Heilwell G, et al. Embryonic stem cell trials for macular  
291 degeneration: a preliminary report. *Lancet*. 2012;379(9817):713-720. doi:10.1016/S0140-  
292 6736(12)60028-2
- 293 21. Schwartz SD, Regillo CD, Lam BL, et al. Human embryonic stem cell-derived retinal  
294 pigment epithelium in patients with age-related macular degeneration and Stargardt’s  
295 macular dystrophy: follow-up of two open-label phase 1/2 studies. *Lancet*.  
296 2015;385(9967):509-516. doi:10.1016/S0140-6736(14)61376-3
- 297 22. Schwartz SD, Tan G, Hosseini H, Nagiel A. Subretinal Transplantation of Embryonic Stem  
298 Cell-Derived Retinal Pigment Epithelium for the Treatment of Macular Degeneration: An  
299 Assessment at 4 Years. *Invest Ophthalmol Vis Sci*. 2016;57(5):ORSFc1-9.  
300 doi:10.1167/iovs.15-18681
- 301 23. Song WK, Park K-M, Kim H-J, et al. Treatment of Macular Degeneration Using  
302 Embryonic Stem Cell-Derived Retinal Pigment Epithelium: Preliminary Results in Asian  
303 Patients. *Stem Cell Reports*. 2015;4(5):860-872. doi:10.1016/j.stemcr.2015.04.005
- 304 24. Hussain RM, Ciulla TA, Berrocal AM, Gregori NZ, Flynn HW, Lam BL. Stargardt macular  
305 dystrophy and evolving therapies. *Expert Opin Biol Ther*. 2018;18(10):1049-1059.  
306 doi:10.1080/14712598.2018.1513486

- 307 25. da Cruz L, Fynes K, Georgiadis O, et al. Phase 1 clinical study of an embryonic stem cell-  
308 derived retinal pigment epithelium patch in age-related macular degeneration. *Nat*  
309 *Biotechnol.* 2018;36(4):328-337. doi:10.1038/nbt.4114
- 310 26. De Silva SR, Charbel Issa P, Singh MS, et al. Single residue AAV capsid mutation  
311 improves transduction of photoreceptors in the *Abca4*<sup>-/-</sup> mouse and bipolar cells in the rd1  
312 mouse and human retina ex vivo. *Gene Ther.* 2016;23(11):767-774. doi:10.1038/gt.2016.54
- 313 27. McClements ME, Barnard AR, Singh MS, et al. An AAV Dual Vector Strategy  
314 Ameliorates the Stargardt Phenotype in Adult *Abca4*<sup>-/-</sup> Mice. *Hum Gene Ther.*  
315 2019;30(5):590-600. doi:10.1089/hum.2018.156

316

**Tables**

317 Table 1. General characteristics of the study population

<b>Characteristics</b>	<b>SD</b> (N=5,015)	<b>SHL</b> (N=369,750)	<b>AMD</b> (N=97,663)
<b>Age, median (IQR) yrs</b>	41 (23 - 53)	54 (44 - 60)	60 (56 - 62)
<b>Sex, no. (%)</b>			
<b>Male</b>	2,257 (45.00)	196,011 (53.01)	40,186 (41.15)
<b>Female</b>	2,758 (55.00)	173,739 (46.99)	57,477 (58.85)
<b>Type of benefit plan, no. (%)</b>	n= 4,600	n=334,156	n=87,576
PPO	98 (2.13)	8,891 (2.66)	3,574 (4.08)
Comprehensive	157 (3.41)	9,026 (2.70)	2,228 (2.54)
EPO	538 (11.70)	42,979 (12.86)	7,918 (9.04)
HMO	336 (7.30)	25,916 (7.76)	7,211 (8.23)
POS	3,036 (66.00)	215,970 (64.63)	59,372 (67.79)
POS with capitation	28 (0.61)	2,084 (0.62)	605 (0.69)
CDHP	209 (4.54)	16,947 (5.07)	3,965 (4.53)
HDHP	198 (4.30)	12,343 (3.69)	2,703 (3.09)

318 SD: stargardt disease, SHL: bilateral sensorineural hearing loss, AMD: non-exudative age related macular  
 319 degeneration, IQR: interquartile range, PPO: preferred provider organization, EPO: exclusive provider  
 320 organization, HMO: health maintenance organization, POS: point-of-service, CDHP: consumer directed  
 321 health plan, HDHP: high deductible health plan



322 Table 2. Most common healthcare services utilized

Healthcare service/CPT code	N (%)
<b>SD</b>	
Fundus photography (92250)	2,614 (11.98)
Medical examination and evaluation (92014)	2,343 (10.74)
Scanning computerized ophthalmic diagnostic imaging of the retina (92134)	1,994 (9.14)
Fluorescein angiography (92235)	1,329 (6.09)
Extended ophthalmoscopy (new visit or diagnosis) (92226)	1,215 (5.57)
<b>SHL</b>	
Comprehensive audiometry threshold evaluation and speech recognition (92557)	308,619 (27.42)
Tympanometry (impedance testing) (92567)	181,190 (16.10)
Tympanometry and reflex threshold measurements (92550)	66,965 (5.95)
Office visit-established patient (99213)	54,304 (4.83)
Office visit-new patient (99203)	34,838 (3.10)
<b>AMD</b>	
Medical examination and evaluation (92014)	57,950 (15.32)
Fundus photography (92250)	51,245 (13.55)
Scanning computerized ophthalmic diagnostic imaging of the retina (92134)	50,508 (13.35)
Extended ophthalmoscopy (new visit or diagnosis) (92226)	27,246 (7.20)
Fluorescein angiography (92235)	21,472 (5.68)

323 CPT: current procedural terminology, SD: stargardt disease, SHL: bilateral sensorineural hearing loss,  
 324 AMD: non-exudative age related macular degeneration

325 Table 3. Multivariable quantile regression for payments per covered year

<b>Stargardt disease</b>		
<b>Variables</b>	<b>Coefficient (95% CI)</b>	<b>P-value</b>
Age	-0.75 (-0.98, -0.53)	<b>0.001</b>
Sex		
Male	Reference	
Female	8.82 (0.98, 16.67)	<b>0.03</b>
Year service was rendered		
2010	Reference	
2011	-29.61 (-40.90, -18.32)	<b>&lt;0.001</b>
2012	-41.52 (-53.22, -29.81)	<b>&lt;0.001</b>
2013	-26.83 (-38.91, -14.74)	<b>&lt;0.001</b>
2014	-27.24 (-39.52, -14.96)	<b>&lt;0.001</b>
Type of benefit plan		
PPO	Reference	
Comprehensive	7.25 (-19.81, 34.31)	0.599
EPO	-6.22 (-27.79, 15.34)	0.572
HMO	-15.73 (-28.06, -3.40)	<b>0.012</b>
POS	-1.60 (-16.76, 13.56)	0.836
POS with capitation	28.66 (-21.34, 78.66)	0.261
CDHP	10.41 (-8.44, 29.26)	0.279
HDHP	6.81 (-12.53, 26.15)	0.490
<b>Bilateral sensorineural hearing loss</b>		
<b>Variables</b>	<b>Coefficient (95% CI)</b>	<b>P-value</b>
Age	-0.32 (-0.34, -0.31)	<b>&lt;0.001</b>
Sex		
Male	Reference	
Female	-3.62 (-4.11, -3.12)	<b>&lt;0.001</b>
Year service was rendered		
2010	Reference	
2011	-16.30 (-17.07, -15.53)	<b>&lt;0.001</b>
2012	-20.54 (-21.31, -19.77)	<b>&lt;0.001</b>
2013	-18.11 (-18.89, -17.32)	<b>&lt;0.001</b>
2014	-12.65 (-13.43, -11.87)	<b>&lt;0.001</b>
Type of benefit plan		
PPO	Reference	
Comprehensive	-1.87 (-3.41, -0.32)	<b>0.018</b>
EPO	6.99 (5.45, 8.52)	<b>&lt;0.001</b>
HMO	-4.17 (-4.93, -3.42)	<b>&lt;0.001</b>
POS	-1.92 (-2.86, -0.98)	<b>&lt;0.001</b>
POS with capitation	-1.35 (-4.49, 1.80)	0.402
CDHP	-2.61 (-3.75, -1.47)	<b>&lt;0.001</b>
HDHP	0.26 (-1.06, 1.58)	0.701
<b>Nonexudative age-related macular degeneration</b>		
<b>Variables</b>	<b>Coefficient (95% CI)</b>	<b>P-value</b>
Age	1.60 (1.44, 1.76)	<b>&lt;0.001</b>

Sex		
Male	Reference	
Female	3.03 (1.69, 4.36)	<0.001
Year service was rendered		
2010	Reference	
2011	-38.54 (-40.48, -36.59)	<0.001
2012	-48.88 (-50.87, -46.89)	<0.001
2013	-47.87 (-49.89, -45.84)	<0.001
2014	-51.77 (-53.82, -49.72)	<0.001
Type of benefit plan		
PPO	Reference	
Comprehensive	-14.68 (-18.04, -11.31)	<0.001
EPO	1.97 (-2.23, 6.17)	0.357
HMO	-4.56 (-6.88, -2.23)	<0.001
POS	-0.62 (-3.05, 1.81)	0.615
POS with capitation	10.02 (2.07, 17.96)	0.014
CDHP	-9.22 (-12.41, -6.03)	<0.001
HDHP	1.72 (-2.11, 5.55)	0.378

326 CI: confidence interval, PPO: preferred provider organization, EPO: exclusive provider organization,  
 327 HMO: health maintenance organization, POS: point-of-service, CDHP: consumer directed health plan,  
 328 HDHP: high deductible health plan

329 Table 4. Payments per covered year for SD vs. SHL

Variables	Coefficient (95% CI)	P-value
Condition		
SD	Reference	
SHL	-47.83 (-49.98, -45.67)	<0.001
Age	-0.33 (-0.34, -0.31)	<0.001
Sex		
Male	Reference	
Female	-3.57 (-4.07, -3.07)	<0.001
Year service was rendered		
2010	Reference	
2011	-16.40 (-17.17, -15.63)	<0.001
2012	-20.67 (-21.44, -19.89)	<0.001
2013	-18.21 (-18.99, -17.42)	<0.001
2014	-12.76 (-13.55, -11.97)	<0.001
Type of benefit plan		
PPO	Reference	
Comprehensive	-1.73 (-3.30, -0.17)	0.030
EPO	6.81 (5.27, 8.35)	<0.001
HMO	-4.23 (-4.99, -3.47)	<0.001
POS	-1.93 (-2.88, -0.99)	<0.001
POS with capitation	-1.13 (-4.30, 2.03)	0.483
CDHP	-2.54 (-3.69, -1.39)	<0.001
HDHP	0.28 (-1.05, 1.61)	0.676

330 CI: confidence interval, SD: stargardt disease, SHL: bilateral sensorineural hearing loss, PPO: preferred  
 331 provider organization, EPO: exclusive provider organization, HMO: health maintenance organization,  
 332 POS: point-of-service, CDHP: consumer directed health plan, HDHP: high deductible health plan

333 Table 5. Payments per covered year for SD vs. AMD

Variables	Coefficient (95% CI)	P-value
<b>Condition</b>		
SD	Reference	
AMD	-17.34 (-22.47, -12.22)	<b>&lt;0.001</b>
Age	1.58 (1.42, 1.74)	<b>&lt;0.001</b>
<b>Sex</b>		
Male	Reference	
Female	3.04 (1.71, 4.37)	<b>&lt;0.001</b>
<b>Year service was rendered</b>		
2010	Reference	
2011	-38.51 (-40.44, -36.59)	<b>&lt;0.001</b>
2012	-48.74 (-50.72, -46.76)	<b>&lt;0.001</b>
2013	-47.71 (-49.73, -45.70)	<b>&lt;0.001</b>
2014	-51.59 (-53.62, -49.55)	<b>&lt;0.001</b>
<b>Type of benefit plan</b>		
PPO	Reference	
Comprehensive	-14.79 (-18.14, -11.44)	<b>&lt;0.001</b>
EPO	1.97 (-2.21, 6.14)	0.356
HMO	-4.79 (-7.10, -2.48)	<b>&lt;0.001</b>
POS	-0.70 (-3.11, 1.72)	0.571
POS with capitation	9.84 (1.92, 17.76)	<b>0.015</b>
CDHP	-8.80 (-11.97, -5.62)	<b>&lt;0.001</b>
HDHP	1.97 (-1.83, 5.78)	0.309

334 CI: confidence interval, SD: stargardt disease, AMD: non-exudative age related macular degeneration,  
 335 PPO: preferred provider organization, EPO: exclusive provider organization, HMO: health maintenance  
 336 organization, POS: point-of-service, CDHP: consumer directed health plan, HDHP: high deductible  
 337 health plan